Deferred Tax Assets, Valuation Allowance of Akero Therapeutics, Inc. from 31 Dec 2017 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Akero Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2024.
  • Akero Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $241,751,000, a 37% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Akero Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $241,751,000 +$64,690,000 +37% 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q4 2023 $177,061,000 +$68,371,000 +63% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q4 2022 $108,690,000 +$41,837,000 +63% 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q4 2021 $66,853,000 +$30,626,000 +85% 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q4 2020 $36,227,000 +$20,715,000 +134% 31 Dec 2020 10-K 17 Mar 2023 2022 FY
Q4 2019 $15,512,000 +$8,712,000 +128% 31 Dec 2019 10-K 25 Feb 2022 2021 FY
Q4 2018 $6,800,000 +$5,438,000 +399% 31 Dec 2018 10-K 16 Mar 2021 2020 FY
Q4 2017 $1,362,000 31 Dec 2017 10-K 16 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.